Format

Send to

Choose Destination
Oncogene. 2016 May 12;35(19):2413-27. doi: 10.1038/onc.2015.318. Epub 2015 Aug 24.

Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes.

Author information

1
Department of Molecular Oncology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
2
K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway.
3
Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
4
MediSapiens Ltd., Helsinki, Finland.

Abstract

Alternative splicing is a widespread process contributing to structural transcript variation and proteome diversity. In cancer, the splicing process is commonly disrupted, resulting in both functional and non-functional end-products. Cancer-specific splicing events are known to contribute to disease progression; however, the dysregulated splicing patterns found on a genome-wide scale have until recently been less well-studied. In this review, we provide an overview of aberrant RNA splicing and its regulation in cancer. We then focus on the executors of the splicing process. Based on a comprehensive catalog of splicing factor encoding genes and analyses of available gene expression and somatic mutation data, we identify cancer-associated patterns of dysregulation. Splicing factor genes are shown to be significantly differentially expressed between cancer and corresponding normal samples, and to have reduced inter-individual expression variation in cancer. Furthermore, we identify enrichment of predicted cancer-critical genes among the splicing factors. In addition to previously described oncogenic splicing factor genes, we propose 24 novel cancer-critical splicing factors predicted from somatic mutations.

PMID:
26300000
DOI:
10.1038/onc.2015.318
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center